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Objective: To probe the effects of qi-supplementing and yin-nourishing therapy (blood-increasing decoction and 
blood generating powder) on chronic thrombocytopenia.  
Methods: Two hundred patients with chronic thrombocytopenia were randomly divided into control (n=100) and 
test groups (n = 100) with Amino-polypeptide as a basic treatment for both. Test group patients consumed a 
blood-increasing decoction and blood-generating powder for 1–3 months. Improvements in platelet counts and 
TCM syndrome were observed.  
Results: One hundred and sixty-four (80 in the test group and 84 in the control group) of 189 total participants were 
treated for 3 months. The total effective rate in improving TCM syndrome was 95.00% in the test group and 79.76% 
in the control group (P<0.05). There was significant difference (P<0.05) in the accumulated score of TCM 
syndrome between the two groups treated at different time points. The total effective rate of platelet counts was 
86.25% in the test group and 59.52% in the control group (P<0.05). There was a significant difference in platelet 
counts before and after treatment in the two groups (P<0.05). There was no significant differences in platelet count 
between the two groups treated for 1–2 months; however, a significant difference was found between the two 
groups after treatment for 3 months (P<0.05).  
Conclusions: After a 3-month treatment of chronic thrombocytopenia patients with qi-supplementing and 
yin-nourishing therapy, TCM syndrome was improved and platelet counts increased with no obvious side effects, 
and the quality of life of the participants was enhanced with noticeable long-term curative effects. 
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TCM syndrome
Chronic thrombocytopenia is caused by a decreased 
quantity or reduced function of blood platelets, leading to 
bleeding. TCM attributes the disease over 12 months to 
purpura. Engaging in clinical research into the disease 
for more than 30 years, our hospital has found that most 
patients with lingering illness have a deficiency or failure 
of qi to control blood and bleeding. Therefore, starting 
from “qi and yin”, we use qi-supplementing and 
yin-nourishing therapy to treat the disease with good 
curative effects. Our research is reported as follows. 
METHODS 
Diagnostic Standards 
Diagnostic standards of thrombocytopenia in Western 
medicine: According to the standard referenced in Zhang 
and Shen:1 1) decreased platelet counts in many tests; 2) 
in chronic thrombocytopenia with platelet counts 80 × 
109/L, no obvious bleeding tendency, only scattered 
bleeding in the skin and mucosa and no bleeding in the 
internal organs; and 3) increased, normal or slightly 
decreased megalocaryocytes in bone marrow tests. 
Diagnostic standards of thrombocytopenia in TCM: 
According to the standard referenced in Zheng:2 1) main 
symptoms are lassitude, dizziness, palpitation, shortness 
of breath, hot sensation in the palms and soles, dry 
mouth and vexation; 2)  secondary symptoms are pale or 
red ecchymosis, poor appetite, dizziness, tinnitus, tidal 
fever, night sweats, red cheeks, pale tongue, decreased or 
thin white body hair and a thready pulse. The disease can 
be diagnosed according to all the main symptoms and 2 
or more of the secondary symptoms in combination with 
tongue and pulse condition. 
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Inclusive Standards 
1) Patients conform to both the diagnostic standard in 
Western medicine and TCM. 2) Patients are 12–80 years 
old. 3) Patients voluntarily attend the test and sign an 
agreement to state understanding of the facts of the 
clinical research. 
Standard for Withdrawal 
Participants who know the facts and conform to the 
standard but have not completed the treatment course or 
cannot continue the test due to serious complications. 
General Data 
Patients from the First Hospital Affiliated to Zhejiang 
TCM University (Zhejiang TCM hospital), Zhejiang 
TCM Academy (Zhejiang Provincial Tongde Hospital), 
Hospital Affiliated to Nanjing TCM University, Jinhua 
Municipal TCM Hospital and Lishui Municipal People’s 
Hospital were randomly divided into groups by computer 
and clinically observed for 3 months using a single-blind 
method. 
Among 189 participants (11 participants not conforming 
to the study guidelines were withdrawn from 200 in the 
total sample) were 95 cases, 33 males and 62 females, 
aged 12–77, with an average age of 39 and an illness 
course from 13 months to 25 years (48.3±54.7 months on 
average) in the test group; and 94 cases, 29 males and 65 
females, aged 13–77, with an average age of 41 and an 
illness course from 14 months to 26 years (43.1±56.9 
months on average) in the control group. There were no 
statistically significant differences in data between the 2 
groups. Among the 189 participants, 182 cases were 
treated for 1 month, 176 cases for 2 months and 164 
cases, 80 cases in the test group and 84 cases in the 
control group, for 3 months. 
Therapy 
In the control group, patients orally consumed 
Amino-polypeptide Tablets (0.2 g/tablet), 1 g a time, 3 
times daily. Amino-polypeptide, produced by Wenzhou 
biochemical pharmaceutical factory, is the main 
ingredient extracted from the nails of pig feet. 
In the test group, in addition to the Amino-polypeptide 
Tablets, patients orally consumed a blood-increasing 
decoction [consisting of 30g Huang Qin (Radix 
astragaliseu hedysari), 15g Bie Jia (Carapax trionycis), 
20g Tai Zi Shen (Radix pseudostellariae), 30g Hai Luo 
(Rapanae thornanianae), 9g Zi Cao (Radix arnebiae seu 
lithospermi), 9g Qian Cao (Radix rubiae) and 15g Gan 
Lu Gen (Rhizoma phragmitis)], one dose a day in the 
morning and evening. Participants also consumed 
blood-generating powder (bone powder produced by our 
hospital, 4.5 g per pack) 1 pack at a time, 2 times daily. 
Because orally taking small dosages of hormones 
(prednisone <20mg a day) cannot be immediately 
stopped or reduced, patients should maintain and 
gradually reduce the dosage according to recovery of the 
condition until eventually the hormone treatment can be 
stopped.  
Observed Index and Method 
Platelet counts (× 109/L). 
Clinical symptoms and signs: Is ecchymosis in the skin 
and mucosa improved? Are there new bleeding points?
TCM symptoms: Are dizziness, lassitude, vexation and 
night sweats improved or alleviated? 
Laboratory index: Is the megalocaryocyte count changed 
in routine examination of the bone marrow? 
Safety indexes: Function of the liver and the kidneys, 
electrocardiogram, and routine urine and stool 
examination. 
Standard for Curative Effect 
Main index for evaluating curative effect: According to 
the standard by Zhang and Shen,1 an obvious effect 
means that platelet counts are >100 × 109/L and bleeding 
has stopped for over 3 months. Effectiveness means that 
platelet counts are >50 × 109/L or increased by 30 × 
109/L as compared with before treatment and bleeding 
has stopped for more than 2 months. Improvement means 
that platelet counts increase and bleeding is improved for 
more than 2 weeks. Ineffectiveness means that platelet 
counts and bleeding are not improved. The total effective 
rate comprises the obvious effect, effectiveness and 
improvement. 
Evaluating curative effect on TCM syndromes: 
According to the standard by Zheng,2 cure means that 
TCM symptoms disappear after treatment, the score for 
syndromes is reduced and the index for curative effects is 
95%. An obvious effect means that after treatment, 
TCM symptoms are remarkably alleviated, syndromes 
are reduced and the index for curative effects is 75% 
but <95%. 
                           Score before treatment – Score after treatment  
Index for curative effect on syndrome = ---------------------------------------------------------× 100% 
                             Score before treatment
Effectiveness means that after treatment, TCM 
symptoms are alleviated, the score for syndromes is 
reduced and the index for curative effects is 30% but 
<75%. Ineffectiveness means that after treatment, TCM 
symptoms are not obviously alleviated and the index for 
curative effects is <30%. The total effective rate 
comprises the obvious effect, effectiveness and 
improvement. 
Statistical Methods 
SPSS 15.0 (SPSS Inc.) was used to carry out statistical 
analysis and x ±s used to express normally distributed 
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data and t-tests conducted for comparisons. 
Non-parametric tests were used for abnormally 
distributed data. P<0.05 was used to indicate statistical 
difference.  
Adverse Incidents and Their Management 
In clinical observation for 1–3 months, routine blood 
tests, hepatic and renal functions, electrocardiogram, and 
routine urine, stool and bone marrow examinations were 
performed regularly. Scores for TCM syndromes were 
evaluated monthly. 
Patients could tolerate mild adverse reactions, which did 
not influence treatment and recovery and needed no 
special management. Because it is difficult for patients to 
tolerate moderate adverse reactions, which directly 
influence recovery, it was necessary for patients to stop 
taking the drug or to be specially treated when such 
reactions became apparent. Because severe adverse 
reactions can jeopardize life or disable patients, it was 
necessary for patients to immediately stop taking the 
drug or to be emergently treated when such reactions 
became apparent. 
RESULTS 
Comparison of the Total Curative Effects on TCM 
Syndromes between the 2 Groups 
As shown in Table 1, the total effective rate in the test 
group was superior to that in the control group (P<0.05). 
Table 1. Analysis of the total curative effect on TCM syndromes after a 3-month treatment (% of cases) 
Group Cases Cure Obvious effect Effectiveness Ineffectiveness Total effectiveness 
Test group 80 18 (22.50) 22 (27.50) 36 (45.00) 4 (5.00) 76 (95.00) 
Control group 84 17 (20.24) 8 (9.52) 42 (50.00) 17 (20.24) 67 (79.76) 
Comparison of the Accumulated Score for TCM 
Syndromes before and after Treatment in the Two 
Groups 
As shown in Table 2, there was a statistically significant 
difference (P<0.05) in the accumulated score for TCM 
syndromes before and after treatment in the two groups, 
and after treatment at different time points between the 2 
groups.  
Comparison of the Total Curative Effects on Platelet 
Count between the Two Groups 
As shown in Table 3, the total effective rate in the test 
group was higher than that in the control group (P<0.05). 
Table 2. Comparison of the accumulated score for TCM syndromes before and after treatment in the two groups 
(score, x ±s) 
Accumulated score for TCM syndromes Group Cases
Before treatment After 1-month treatment After 2-month treatment After 3-month treatment 
Test group 80 18.78±10.09 12.14±7.93Ƹ   8.12±5.90Ƹ   6.33±4.19Ƹ
Control group 84 20.82±11.64 15.53±10.83 10.74±9.43 10.89±8.44
Notes: *P<0.05 as compared with the score before treatment in the same group;ƸP<0.05 as compared with the score after treatment for 
same time in the control group. 
Table 3. Analysis of the total curative effects on platelet count after a 3-month treatment between the two groups 
(% of cases)
Group Cases Cure Obvious effect Effectiveness Ineffectiveness Total effectiveness 
Test group 80 9 (11.25) 34 (42.50) 26 (32.50) 11 (13.75) 69 (86.25) 
Control group 84 7 (8.33) 23 (27.38) 20 (23.81) 34 (40.48) 50 (59.52) 
Comparison of Platelet Count before and after 
Treatment in the Two Groups 
As shown in Table 4, there was a statistically significant 
difference (P<0.05) in platelet counts after treatment for 
3 months and no significant difference after treatment for 
1 or 2 months in the two groups.
Table 4. Comparison of platelet counts before and after treatment in the two groups (×109/L, x ±s˅
Accumulated score for TCM syndromes Group Cases
Before treatment After 1-month treatment After 2-month treatment After 3-month treatment 
Test group 80 44.57f18.64 52.70f35.94 62.18f43.86 75.59f54.36
Control group 84 42.32f20.25 52.09f31.43 63.42f30.11 60.79f32.37
Notes: P<0.05 as compared with the value before treatment in the same group;P<0.05 as compared with the value after treatment for same 
time in the control group.  
Adverse Reactions 
No effect of the test drug was found on indexes of 
hepatic and renal function, electrocardiogram, or routine 
urine and stool tests in the follow-up visit. However, 
during the research, after taking the test drug, 2 patients 
had loose stool and 3 patients had a mild reaction in the 
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gastrointestinal tract. The 5 patients with no special 
treatment continued taking the drug for 2–3 days and 
their symptoms were alleviated automatically.  
DISCUSSION  
Thrombocytopenia is mainly treated by clearing away 
heat from the blood, removing toxins, promoting blood 
circulation, and by supplementing qi and nourishing yin. 
Supplementing the bone marrow, replenishing the bone 
and generating blood can repair the damaged organs and 
improve symptoms.  
Based on long-term research into thrombocytopenia, we 
have found that most patients with chronic 
thrombocytopenia display a deficiency of both qi and yin. 
“Qi as the commander of blood” and “blood being the 
mother of qi” are the cause and result of each other. Only 
by treating the disease at the early stage with 
qi-supplementing and yin-nourishing drugs can the 
development of the illness be obstructed.4 Long-term 
thrombocytopenia mentioned by Cui Xujiang5 seemingly 
belongs to the category of “yin” and “deficiency”. It has 
been discovered in clinical research that a 
qi-supplementing and yin-nourishing method 
(blood-increasing decoction and blood-generating 
powder) can improve the TCM symptoms of chronic 
thrombocytopenia very well and reduce side-effects of 
immune inhibition. A 3-month treatment can enhance 
platelet counts, reduce bleeding risk and improve quality 
of life. We also have found that a good curative effect is 
achieved without hormone treatment, a poor curative 
effect is achieved with hormone treatment, and that no 
curative effect is achieved with repeated use of hormone 
treatment. 
“Blood-generating powder”, a proven recipe developed 
by famous veteran TCM physicians in our hospital, has 
been used for many years to treat all kinds of 
thrombocytopenia and some kinds of leucopenia caused 
by long-term contact with radioactivity, with a good 
curative effect achieved and some research 
accumulated.6 A blood-increasing decoction, consisting 
of Huang Qi (Radix astragali seu hedysari), Bie Jia 
(Carapax trionycis), Tai Zi Shen (Radix 
pseudostellariae), Hai Luo (Rapanae thornanianae), Zi 
Cao (Radix arnebiae seu lithospermi), Qian Cao (Radix 
rubiae) and Gan Lu Gen (Rhizoma phragmitis), can 
supplement qi and nourish yin. Modern pharmacological 
research shows that most drugs in the recipe have good 
effects on regulating immunity and stopping bleeding. 
Huang Qi, sweet in taste and slightly warm in nature, 
with its therapeutic action related to channels of the 
spleen and lung, has the effect of supplementing qi, 
consolidating superficial resistance, astringing sweating, 
discharging toxins, generating tissue, causing diuresis 
and subduing swelling. Jiao Zhonghua has achieved a 
good curative effect of Huang Qi in a 
purpura-eliminating decoction.7 Zhang Haowen and 
others8 indicate that Huang Qi has the effect of 
supplementing qi and generating blood. Danggui Buxue 
Tang, an ancient recipe, can treat poor qi, blood 
deficiency and other deficiency syndromes. Modern 
pharmacological research indicates that Huang Qi has an 
obvious effect on regulating immunity and promoting the 
maturity of megalocaryocytes.9 Zi Cao has the effect of 
clearing away heat from the blood, promoting blood 
circulation, removing toxins and promoting eruption. Li 
Hong10 has used Zi Cao to treat colporrhagia after 
miscarriage with an obvious effect, indicating that Zi 
Cao can reduce the amount of bleeding and shorten 
bleeding time. Research shows that Zi Cao can inhibit 
damage to the vascular endothelium caused by immune 
compounds.11 Qian Cao has the effect of clearing away 
heat from the blood, stopping bleeding, promoting blood 
circulation and removing blood stasis. Song Shanjun and 
others12 have discovered through in vitro experiments 
that Qian Cao can promote the generation of 
thromboplastin, thrombase and fibrin, and that its 
coagulation effects may be related to the effect of 
anti-heparin.13 Tai Zi Shen can nourish the spleen and 
lungs, supplement qi and generate body fluids. Modern 
pharmacological research proves that it can strengthen 
immunity.14 Animal experiments have shown that a 75% 
alcoholic extract of Tai Zi Shen can inhibit a reduction in 
the weight of the thymus gland and the spleen caused by 
cyclophosphamide and increase levels of expression of 
DNA and RNA in the thymus gland as well as DNA in 
the spleen.15,16  
In the current research, 2 patients had loose stool and 3 
patients had a mild reaction in the gastrointestinal tract. 
These 5 patients were not specially treated and their 
symptoms resolved automatically. The reaction is related 
to the medicinal nature of Bie Jia, which is slightly cold 
in nature and salty in taste, with a therapeutic action 
related to the channels of the liver and kidneys, 
nourishing yin, checking the exuberance of yang, and 
softening and resolving hard mass. Some patients with a 
cold syndrome of the stomach who cannot tolerate the 
cold nature of Bie Jia have a mild reaction of the 
gastrointestinal tract and loose stool. Modern 
pharmacological research proves that the bioactive 
substance extracted from Bie Jia has the effect of 
inhibiting tumor growth and radiation damage as well as 
enhancing immune function.17,18 Research by Wang 
Huiming and others19 has shown that a polysaccharide of 
Bie Jia can enhance nonspecific immune function in 
immunosuppressant mice with a dose-dependent effect. 
Thrombocytopenia patients have a disorder of humoral 
immunity and an abnormality of cytoimmunity. 
Disorders of the immunoregulation mechanisms of 
T-cells play a very important role in the occurrence of the 
disease.20 Professor Ma Rou has pointed out that scholars 
had attached importance to the effects of abnormally 
oligocloned T- and B-lymphocytes on destroying 
platelets in the occurrence of the disease.21 Our clinical 
research finds that there is an obvious difference in the 
expression of a subgroup of T-lymphocytes in peripheral 
blood before and after treatment of thrombocytopenia 
with blood-increasing and blood-generating therapy; a 
marked increase in the expression of CD3+ and CD4+, a 
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remarkable decrease in the expression of CD8+ and a 
noticeable increase in the ratio of CD4+ to CD8+ after 
treatment, indicating that the recipe does have the effect 
of regulating the expression of a subgroup of 
T-lymphocytes in the peripheral blood of 
thrombocytopenia patients.22
Despite our significant results, limitations of the current 
study include the different compliance rates of 
participants and a single index for evaluating curative 
effects. Therefore, in our future research, we will 
consider using additional laboratory indexes such as the 
level of expression of human leukocyte antigen DR 
(HLADR) and a specific antibody of platelets (PBIgG). 
The HLADR locus as a marker of the activation of 
T-cells.23 Yang Xiaohong and others24 have found that a 
CD3+/HLADR+ subgroup of T-cells are significantly 
increased in patients with refractory ITP, indicating that 
HLADR is related to prognosis of ITP. Song Qiang25 and 
others have found that the level of expression of HLADR 
in ITP patients is much higher than that in the control 
group, indicating that abnormal activation of T-cells and 
HLADR is related to the occurrence of ITP. We also have 
discovered that qi-supplementing and yin-nourishing 
therapy can improve some symptoms of chronic 
thrombocytopenia patients with a deficiency of both qi 
and yin. However, some patients mainly have a yin
deficiency while others mainly have a qi deficiency. 
Therefore, we will regulate drugs appropriately so as to 
observe the difference in the curative effects and the 
direct clinical use of drugs in a better way. 
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